| Interphase | Prophase | Metaphase | Anaphase | Telophase | Apoptosis | Abnormal |
---|
Medium
| 96.1% | 0.6% | 1.5% | 0.4% | 0.6% | 0.5% | 0.4% |
DMSO
| 97.5% | 0.2% | 1.3% | 0.2% | 0.6% | 0.2% | 0.4% |
Actinomycin D
| 60.2% | 0.3% | 2.5% | 0% | 0.5% | 33.8% | 2.3% |
ESE-16 | 27.3% | 0.7% | 46.0%* | 0.2% | 0.4% | 21.4%* | 4.2% |
- Mitotic indices revealed a significant increase, with a P-value of 0.0003*, in the percentage of cells in metaphase in the ESE-16-treated samples (46.0%) when compared to the vehicle control (1.3%). ESE-16-treated cells also showed a significant increase (P-value of 0.0006*) in the percentage of cells undergoing apoptosis (21.4%) when compared to the vehicle control (0.2%).